Status of progression of development in middle adulthood

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of albuminuria in T2DM patients, with microalbuminuria reduced by 8.1% (p=0.01) and macroalbuminuria reduced by 14.6% (p=0.03) compared with simvas

Effect: improvement; Microalbuminuria -8.1%, macroalbuminuria -14.6%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%